Regenxbio (RGNX) Misses Q4 EPS by 14c

Regenxbio (NASDAQ: RGNX) reported Q4 EPS of ($1.38), $0.14 worse than the analyst estimate of ($1.24). Revenue for the quarter came in at $31.35 million versus the consensus estimate of $39.41 million.

For earnings history and earnings-related data on Regenxbio (RGNX) click here.

You May Also Be Interested In

• Regenxbio Inc. (RGNX) PT Raised to $32 at Baird
• Regenxbio shares jump after FDA agrees to reverse drug rejection
• Bristow Group to acquire Berry Aviation for $105 million